Grant P. Janzen, M.D.
Diseases and Surgery of the Retina and Vitreous
West Texas Retina Consultants/Retina Research Institute of Texas

EDUCATION

M. D., University of Oklahoma College of Medicine, Oklahoma City, Oklahoma
August 2000-May 2004

B.S. Biology, Oklahoma Baptist University, Shawnee, Oklahoma
August 1996-December 2000

University of Oklahoma Study Abroad Program (Linkoping, Sweden)
European history and culture
January 2000-June 2000

University of Oklahoma Biological Station at Lake Texoma
July 1997-August 1997

RESIDENCY

Medical University of South Carolina:

Surgical Internship (PGY-1) July 1, 2004-June 30, 2005

Ophthalmology Residency (July 1, 2005-June 30, 2008)

FELLOWSHIP

Tufts/New England Eye Center and Ophthalmic Consultants of Boston
Vitreoretinal Disease and Surgery
July 7, 2008-July 7, 2010

EMPLOYMENT

Staff Vitreoretinal Surgeon
West Texas Retina Consultants
Abilene, TX
August 2010-present

Staff Investigator
Retina Research Institute of Texas
Abilene, TX
August 2010-present

Staff Investigator

Strategic Clinical Research Group
101 Chuckwagon Trail
Willow Park, TX 76087
2015-2016

CURRENT RESEARCH

Sub Investigator. **Genentech Omaspect GX30191**, A Multicenter, Open-Label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with Geographic Atrophy secondary to age-related Macular Degeneration who have completed a Roche sponsored study. (July 2016 – Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub Investigator. **Ora Acucela 4429-203**, A multi-center, randomized, double-masked, placebo-controlled, pilot study to evaluate effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers associated with Proliferative Diabetic Retinopathy. (April 2016 - Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub-Investigator. **Regeneron Ruby R910-3-DME-1518**, A randomized, double-masked, active-controlled, phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with Diabetic Macular Edema. (March 2016 – Present)
Principal Investigator: Eric Zaveleta, M.D.
Sub Investigator: Sunil S. Patel M.D. PhD, S. Young Lee M.D.

Sub Investigator. **Genentech Boulevard BP30099**, A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with Diabetic Macular Edema. (February 2016 – Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub Investigator. **Genentech Chroma GX29176**, A Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with Geographic Atrophy secondary to age-related Macular Degeneration. (February 2016 – Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub Investigator. **Regeneron Onyx R910-3-AMD-1517**, A randomized, double masked, active controlled Phase II study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with Neovascular age-related Macular Degeneration. (February 2016 – Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub Investigator. **Ophthotech Zimura OPH2003**, A Phase II/III randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreous administration of Zimura (Anti-

C5 Aptamer) in subjects with Geographic Atrophy secondary to dry age-related Macular Degeneration. (November 2015 – Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub Investigator. **Regeneron Panorama VGFTe-OD-1411.02**, A Phase III, double-masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe non-proliferative Diabetic Retinopathy. (October 2015 – Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub Investigator. **Daiichi Sankyo Pharma DS7080-A-U101**, Phase I dose escalation and expansion study of DS-7080a in subjects with Neovascular age-related Macular Degeneration. (October 2015 – Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub Investigator. **Opthea OPT-302**, A Phase I dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of OPT-302 in combination with Ranibizumab in subjects with Wet AMD. (October 2015 – Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub Investigator. **Apellis Filly POT-CP121614**, A Phase II, multicenter, randomized, single-masked, Sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 Therapy in patients with Geographic Atrophy (GA). (September 2015 – Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Principal Investigator. **Allegro PVD-202**, A Phase II, randomized, double-masked, placebo-controlled multicenter clinical trial designed to evaluate the safety and efficacy of Luminate in inducing PVD in subjects with Non-Proliferative Diabetic Retinopathy. (June 2015 – Present)
Sub-Investigator: Sunil S. Patel M.D. PhD, S. Young Lee M.D., Eric Zaveleta, M.D.

Sub Investigator. **Genentech Avenue BP29647**, A multi-center, multiple-dose and regimen, randomized, active comparator controlled, double-masked, parallel group, 36-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with Choroidal Neovascularization secondary to age-related Macular Degeneration. (June 2015 – Present)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Principal Investigator. **Ophthotech OPH1004**, A Phase III randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista (Anti PDGF-B Pegylated Aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with Subfoveal Neovascular age-related Macular Degeneration. (April 2015 – Present)
Sub-Investigator: Sunil S. Patel M.D. PhD, S. Young Lee M.D., Eric Zaveleta, M.D

Principal Investigator, Ophthotech OPH1002, "A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista™ (Anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis® Monotherapy in subjects with Subfoveal Neovascular Age-Related Macular Degeneration
Sub-Investigator: Eric Zavaleta, M.D., Sunil S. Patel, M.D., PhD, S. Young Lee, M.D.
August 2013- Present

Sub-Investigator, Xcovery Vision, LLC. X82-OPH-102, A Phase 1/2 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 administered per Os on Subjects with Neovascular Age-related Macular Degeneration (AMD)
Principal Investigator: Sunil S. Patel, M.D., PhD
Sub-Investigator: Grant P. Janzen, M.D., S. Young Lee, M.D., Eric Zavaleta, M.D.
May 2013-Present

Sub-Investigator, Genentech OLEi GX28198, "A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of FCFD4514S in patients with Geographical Atrophy"
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D
April 2012-Present

Sub Investigator. **Iconic Therapeutics IT-002**, A Phase II randomized, double-masked, multicenter, active-controlled study evaluating administration of repeated intravitreal doses of hI-con1 in patients with Choroidal Neovascularization secondary to age-related Macular Degeneration. (June 2015 – Nov 2016)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub Investigator. **Genentech Ladder GX28228**, A Phase II, multicenter, randomized, active treatment controlled study of the efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with Subfoveal Neovascular age related Macular Degeneration. (May 2015 – Oct 2016)
Principal Investigator: Sunil S. Patel, M.D. PhD
Sub-Investigator: S. Young Lee M.D., Eric Zaveleta, M.D.

Sub-Investigator, Ampio Pharmaceuticals, Inc. AP-05-002, A Randomized, Placebo Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina™ in adult Patients with Diabetic Macular Edema
Principal Investigator: Sunil S. Patel, M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.
July 2013- April 2014

Sub-Investigator, Aerpio Therapeutics, Inc. AKB-9778, A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center study to assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema
Principal Investigator: Sunil S. Patel, M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.
March 2014-June 2015

Sub-Investigator, StemCells, Inc. CL-N01-AMD, Phase I/II Study of the Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-Sc) Subretinal Transplantation in Subjects with Geographical Atrophy of Age-Related Macular Degeneration.
Principal Investigator: Sunil S. Patel, M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.
January 2014-2015

Sub-Investigator, PanOptica, Inc. PAN-01-101, A Phase 1 Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD)
Principal Investigator: Sunil S. Patel, M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.
January 2014-March 2016

Sub-Investigator, Regeneron RE-VIEW VGFTe-AMD-1124, "An Open-Label Study of the efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-EYE (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration"
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.
February 2013-November 2015

Sub-Investigator, Regeneron VIBRANT VEGFe-RVO-1027, "A double-Masked, Randomized, Active-Controlled Study of the Efficay, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D
May 2012-June 2014

Sub-Investigator, Allergan REACH AGN-150998, "Single and Repeat Dose of the Safety and Efficacy of AGN-150998 in patients with Exudative Age-related Macular Degeneration"
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D., Eric M. Zavaleta, M.D.
July 2011-July 2014

Sub-Investigator, Lpath NEXUS LT1009-Oph-003, "A phase 2A, Multi-Center, Masked, Randomized, Comparator-Controlled Study Evaluating iSonep ™(Sonepcizumab [LT1009]) As either Monotherapy or adjunctive Therapy to Lucentis® or Avastin® Alone for the treatment of subjects with choroidal Neovascularization Secondary to Age-Related Macular Degeneration"
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D., Eric M. Zavaleta, M.D.
July 2011-March 2015

Sub-Investigator, GlaskoSmithKline BAM114341, "A Phase II, Multi-centre, Randomised, Double-Masked, Placebo-Controlled, Parallel-Group Study to investigate the Safety, Tolerability, Efficacy,
Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographical Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)"
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
February 2011-July 2016

Primary Investigator, Regeneron Vista VGFT-OD-1009, "A Double-Masked, Randomized, Active-Controlled, Phase III Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema"
Sub-Investigator: Sunil S. Patel, M.D., PhD,
Sub-Investigator: S. Young Lee, M.D., Eric M. Zavaleta, M.D.
February 2011-December 2014

Sub-Investigator, Allergan 190342-033D, "A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the biodegradation of the brimonidine Tartrate Posterior Segment Drug Delivery System."
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
September 2010-2014

Sub-Investigator, Alcon Research, Ltd. C-13-001, A Prospective, Two-Cohort, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection of Infusion in Subjects with Exudative Age-Related Macular Degeneration
Principal Investigator: Sunil S. Patel, M.D., PhD
Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.
July 2013-February 2014

Sub-Investigator, Allergan 206207-024, "A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of 700ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema"
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D
February 2012-March 2014

Sub-Investigator, Novartis CLFG316A2202, "A Multicenter, Randomized, Sham-Controlled, Repeat-Dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients with Neovascular Age-Related Macular Degeneration"
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: S. Young Lee, M.D
February 2012-December 2013

Sub-Investigator, Alimera FAME C-01-11-008, "An Open Label, Multi-center Extension Study of the Safety and Utility of the New Inserter of Iluvien ® (Fluocinole Acetonide Intravitreal Insert) 0.19mg and the Safety of Iluvien in subjects with Diabetic Macular Edema"
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
March 2011-November 2013

Sub-Investigator, Allergan BDP 208397-001, "A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)"
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
April 2011-May 2013

Sub-Investigator**,** Pfizer B1181003, "A Phase 2 Multi-Center, Randomized, Double-Masked Placebo-Controlled, Multi-Dose Study to Investigate the Efficay, Safety, Pharmacokinetics and Pharmacodynamics of RN6G (PF-04382923) In Subject with Geographic Atrophy Secondary to Age-Related Macular Degeneration"
Primary Investigator: Sunil S. Patel M.D., PhD
Sub-Investigator: Grant P. Janzen, M.D
October 2012-April 2013

Sub-Investigator, Pfizer B1181002, "A Phase I, Double-masked, Placebo-controlled study evaluating the Safety and Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Dosages of RN6G (PF-04382923) in subjects with Advanced Dry, Age-Related Macular Degeneration (AMD) including Geographical Atrophy"
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
September 2010-March 2013

Sub-Investigator, Genentech Shore FVF4967g, "A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab in Subjects with Macular Edema Following Retinal Vein Occlusion."
Primary Investigator: Sunil S. Patel, M.D., PhD
Sub-Investigator: S. Young Lee, M.D.
September 2010-January 2013

Sub-Investigator, Lpath Incorporated LT1009-OPH002, "A Phase 1B Multicenter, Open-Label and Randomized study of ISONEP (Sonepcizumab/LT1009) administered as Intraveneous Injections to subjects with PED Secondary to Exudative Age-Related Macular Degeneration or Polypoidal Choroidal Vasculopathy."
Primary Investigator: Sunil S. Patel, M.D., PhD
Sub-Investigator: S. Young Lee, M.D.
September2010-November 2012

Sub-Investigator, Genentech FVF4579g Harbor, "A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the efficacy and safety of 0.5mg and 2.0 mg Ranibizumab administered monthly or an as-needed basis (PRN) in patients with Subfoveal Neovascular Age-related Macular Degeneration."
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
September 2009-September 2012

Sub-Investigator, Genentech Mahalo CFD4870g, "A Phase Ib/II, Multicenter, Randomized, Single Masked, Sham-Injection-Controlled study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered monthly or Every other month to patients with Geographical Atrophy."
Primary Investigator: Sunil S. Patel, M.D., PhD
Sub-Investigator: S. Young Lee, M.D.
September 2010-April 2012

Sub-Investigator, Ophthotech OPH1001, "A PHASE 2, Randomized, Double-Masked, Controlled trial to establish the safetyu and efficacy of intrvitreous injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in combination with Lucentis® in subjects with Neovascular Age-Related Macular Degeneration"

Primary Investigator: Sunil S. Patel M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
September 2010-March 2012

Sub-Investigator, Victor Gonzales, M.D.,PRESERVE, "Pegaptanib for Retinal Edema Secondary to DiabeticVascular Disease."
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
September 2010-December 2011

Sub-Investigator, Alcon C-08-36 (GATE), "The safety and efficacy of AL-8309B ophthalmic Solution for the treatment of Geographical Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)."
Primary Investigator: Sunil S. Patel M.D., Ph.D
Sub-Investigator: S. Young Lee, M.D.
September 2010-September 2012

Sub-Investigator, Ophthotech OPH3000ss, "A phase I ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokenetics profile of multiple intravitreous injections of Volociximab (α5β1 integrin antagonist as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with Neovascular Age-Related Macular Degeneration."
Primary Investigator: Sunil S. Patel, M.D., Ph.D.
Sub-Investigator: S. Young Lee, M.D.
September 2010-December 2011

PREVIOUS RESEARCH EXPERIENCE

Clinical Trial Co Investigator
Tufts/New England Eye Center and Ophthalmic Consultants of Boston
July 7, 2010

Tufts and Ophthalmic Consultants of Boston

Regeneron	VGFT0819/Copernicus
Genentech	CFD4711g
Genentech	HARBOR
Alimera	FAVOR
Alcon	WALTZ
Allergan	Brimo RD
Molecular Partners	MPAG1
NIH	AREDS2
Alcon	GATE
Genentech	Horizon RVO
Neovista	ROSE
John Hopkins/Wilmer Eye Institute	READ2
Regeneron	VGFT 0702
Regeneron	VGFT0706/DME
Regeneron	VGFT0605/VIEW

CFD4711g: “A Phase 1a, Multicenter, Open-Label, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients with Geographic Atrophy.”
Copernicus: “VGFT-OD-0819 A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).”

FAVOR: “A Randomized, Single-Masked, Pilot Study of the Safety and Efficacy of 0.5 micrograms/day and 0.2 micrograms/day Iluvien 0.19mg in Subjects with Macular Edema Secondary to RVO.”

HARBOR: “FVF4579g: A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration.”

WALTZ: “A Dose-Escalation Study of AL-39324 Suspension versus Lucentis for the Treatment of Exudative Age-Related Macular Degeneration.”

AREDS2: “AREDS II – Age-Related Eye Disease Study II.”Cortiject: “NVG07D108 – A Phase I, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of NOVA63035 in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy.”

GATE: “C-08-36 – The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration.”
Horizon RVO: “FVF3426g (HORIZON) – An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) who Have Completed a Genentech-Sponsored Ranibizumab Study.”

Jerini: “JO642701 – A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmakokinetic Profile of Single and Repeated Doses of JSM6427 Following Administration by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration.”

NeoVista Rose: “NVI-006 (Rose): A Feasibility Study to Evaluate the Safety and Tolerability of the Epi-Rad90 Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization (CNV) in Patients with Age-Related Macular Degeneration (AMD) that have Failed anti-VEGF Therapy.”

READ2: “READ2 – Ranibizumab for Edema of the Macula in Diabetes: A Phase 2 Study.”

VGFT 0702: “VGFT-OD-0702 – Extension trial for VGFT-OD-0508 An Open-Label, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration.”

VGFT 0706 (DME): VGFT-OD-0706 – A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME).

VIEW: "VGFT-OD-0605 – A Randomized, Double-Masked, Active-Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular AMD."

Brimo RD: "A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 12 Month Study to Evaluate the Safety and Effects on Visual Function of Brimonidine Tartrate PS DDS Applicator System in Patients with a Previous Rhegmatogenous Macula-Off Retinal Detachment."

GENZ1: "A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLTO1 in Patients with Neovascular Age-Related Macular Degeneration."

MPAG1: "A Phase I/II, Open-Label, Single Ascending Dose Study Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of Intravitreal MP0112 in Patients with Diabetic Macular Edema (DME)."

Paloma AMD: "A Phase I Single-center Study of the Safety and Tolerability of Intravitreal Injection of Paloma Compound A for the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration."

PUBLICATIONS/BOOK CHAPTERS

Janzen GP and Heier JS. Anti-VEGF Therapies in ARMD in Clinical Practice. In: Das A and Friberg T, eds. *Therapy of Ocular Angiogenesis: Principles and Practice.* 1st edition, Baltimore: Wolters-Kluwer, Lippincott, Williams and Wilkins, 2011;PGS 102-118

Goren JF, Shah SP, Janzen GP,Gross NE, Duker JS. Diffuse Retinal Pigment Epithelial Disease in an Adult Patient with Cystic Fibrosis. Ophthalmic Surg Lasers Imaging. 2011 Jun 9;42 online:e56-8.

Manjunath V, Shah SP, Janzen GP, Rogers A, Baumal C, Reichel E, Duker JS. Comparative Analysis of Optical Coherence Tomography Imaging Through Gas Filled Eyes. Manuscript for Retina.

Ho J, Semela LB, Smithen L, Janzen G, Chen Y, Liu JJ, Fujimoto JG, Schuman JS, Duker JS. Comparison of Time Domain to Spectral Domain Optical Coherence Tomography Imaging in High Myopic Patients. Manuscript in preparation for Archives of Ophthalmology.

PRESENTATIONS

Janzen GP, Ho J, Smithen L, Chen Y, Lin JJ, Fujimoto JG, Schuman JS, Duker JS. Analysis of Time and Spectral / Fourier Domain Optical Coherence Tomography Imaging of Patients with High Axial Myopia. (5-5-09) The Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, Florida.

Janzen GP. (5-31-2007) "Corneal Dystrophy in a South Carolina Family." ASCRS Spring Update at Kiawah, South Carolina

Chavis PS and Janzen GP (9-22-2006) "The Painful Eye." JCAHPO Hilton Head Regional Education Program

Janzen GP. (8-10-2006) "Eye Findings in Dermatologic Disease." MUSC Dermatology Grand Rounds, Charleston, South Carolina

Janzen GP. (4-22-2006) "Post-LASIK Corneal Scarring." Third Annual Southeast Cataract, Cornea, and Refractive Surgery Conference at Emory University, Atlanta, Georgia

Janzen GP. (6-1-2006) "Pterygoid Corneal Dystrophy." ASCRS Spring Update at Kiawah, South Carolina

Janzen GP. (7-21-2003) "Hypertensive Retinopathy." Dean McGee Eye Institute Grand Rounds, Oklahoma City, Oklahoma

Janzen GP and Janzen JE. (2003) "Erythema Multiforme: Drug vs Bug." University of Oklahoma Tulsa Research Day 2003, Tulsa, Oklahoma

HONORS AND AWARDS

MUSC Applause Award for Patient Care, 2005

All American Scholar-Athlete (tennis)

Men's Varsity Tennis Team Captain and Leadership Award, 1998-1999

Principal Violin, Oklahoma Baptist University Orchestra

PROFESSIONAL SOCIETIES

Diplomat, American Board of Ophthalmology

Member, American Academy of Ophthalmology

Member, American Society of Retinal Specialists

INTERESTS

Family (wife and four children), violin, cooking, tennis, flyfishing, traveling